Terms ending in 2039
Every in-force patent on Indi Molecular, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,884,707 | Compositions for Detection, Inhibition and Imaging of Indoleamine 2, 3-Dioxygenase 1 (IDO1) and Methods of Making and Using Same In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,594,350 | CD8-SPECIFIC Capture Agents, Compositions, and Methods of Using and Making In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,919,972 | Peptide Libraries with Non-Canonical Amino Acids In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,638,764 | Theranostic Capture Agents, Compositions, and Methods of Using and Making In force · High confidence | Indi Molecular, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Indi Molecular, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.